Ambulatory Parkinson's Disease Dyskinesia Monitor for Drug Therapy Titration

Completed

• Conditions: Parkinson's Disease

• Registration Number: NCT02125825
• Lead Sponsor: Great Lakes NeuroTechnologies Inc.

Brief Summary

The objective is to assess a compact, portable, wireless movement disorder system with continuous monitoring capabilities to detect and quantify the severity of levodopa-induced dyskinesia in Parkinson's disease.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2014-04-25
• Study First Submitted QC: 2014-04-25
• Study First Posted: 2014-04-29
• Study Start: 2014-07
• Primary Completion: 2014-12
• Study Completion: 2014-12
• Status Verified: 2016-01
• Last Update Submitted: 2016-01-08
• Last Update Posted: 2016-01-12

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 14

Inclusion Criteria

• Diagnosis of idiopathic Parkinson's disease
• Clinical history of levodopa-induced dyskinesia
• 21 Years of age or older
• Stage 2 - 4 OFF-medication on the Hoehn and Yahr scale

Exclusion Criteria

• Dementia (determined by a neuropsychological assessment)
• Severe tremor unaffected by levodopa

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Correlation between motion sensor features and clinician-rated dyskinesia severity	All data will be collected within a single session not to exceed 3 hours	Motor function (movement speed and magnitude measured with a motion sensor) will be collected for a period of 2 hours after taking normally prescribed dose of levodopa.

Trial Locations

Locations (2)

Johns Hopkins Medical Center; 🇺🇸 Baltimore, Maryland, United States

University of Rochester Medical Center; 🇺🇸 Rochester, New York, United States